Lergotrile | CAS#36945-03-6 | enzyme Inhibitor

MedKoo Cat#: 559007 | Name: Lergotrile

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lergotrile is an enzyme Inhibitor (Prolactin).

Chemical Structure

Lergotrile

CAS#36945-03-6

Theoretical Analysis

MedKoo Cat#: 559007

Name: Lergotrile

CAS#: 36945-03-6

Chemical Formula: C17H18ClN3

Exact Mass: 299.1189

Molecular Weight: 299.80

Elemental Analysis: C, 68.11; H, 6.05; Cl, 11.82; N, 14.02

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Lergotrile; 79907; LY 79907; LY-79907; LY79907;

IUPAC/Chemical Name

2-((6aR,9S,10aR)-5-chloro-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl)acetonitrile

InChi Key

JKAHWGPTNVUTNB-IXPVHAAZSA-N

InChi Code

InChI=1S/C17H18ClN3/c1-21-9-10(5-6-19)7-12-11-3-2-4-14-16(11)13(8-15(12)21)17(18)20-14/h2-4,10,12,15,20H,5,7-9H2,1H3/t10-,12-,15-/m1/s1

SMILES Code

[H][C@@]1(N(C)C[C@H](CC#N)C[C@@]12[H])CC3=C(Cl)NC4=C3C2=CC=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 299.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Cunningham KA, Callahan PM, Appel JB. Discriminative stimulus properties of lergotrile. J Pharmacol Exp Ther. 1984 Jul;230(1):47-52. PubMed PMID: 6146709. 2: Fuller RW, Perry KW. Effect of lergotrile on 3,4-dihydroxyphenylacetic acid (DOPAC) concentration and dopamine turnover in rat brain. J Neural Transm. 1978;42(1):23-35. PubMed PMID: 641542. 3: Lieberman AN, Gopinathan G, Estey E, Kupersmith M, Goodgold A, Goldstein M. Lergotrile in Parkinson disease: further studies. Neurology. 1979 Feb;29(2):267-72. PubMed PMID: 34808. 4: Schmidt MJ. Dopamine agonist-induced hyperglycemia in rats: effects of lergotrile mesylate. Eur J Pharmacol. 1979 Oct 26;59(1-2):95-101. PubMed PMID: 41730. 5: Teychenne PF, Pfeiffer RF, Bern SM, McInturff D, Calne DB. Comparison between lergotrile and bromocriptine in parkinsonism. Ann Neurol. 1978 Apr;3(4):319-24. PubMed PMID: 666273. 6: Rubin A, Lemberger L, Dhahir P, Warrick P, Crabtree RE, Obermeyer BD, Wolen RL, Rowe H. Physiologic disposition of lergotrile. Clin Pharmacol Ther. 1978 Mar;23(3):272-80. PubMed PMID: 627132. 7: Lew JY, Hata F, Ohashi T, Goldstein M. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors. J Neural Transm. 1977;41(2-3):109-21. PubMed PMID: 21229. 8: Barrett RJ, Lokhandwala MF. Presynaptic dopamine receptor stimulation in the cardiovascular actions of lergotrile. J Pharmacol Exp Ther. 1981 Jun;217(3):660-5. PubMed PMID: 6112262. 9: Lieberman A, Estey E, Kupersmith M, Gopinathan G, Goldstein M. Treatment of Parkinson's disease with lergotrile mesylate. JAMA. 1977 Nov 28;238(22):2380-2. PubMed PMID: 335094. 10: Bergmann F. Stereotyped responses of rats to two 2-halogenoergolines: 2-bromo-alpha-ergocryptine and lergotrile. Isr J Med Sci. 1982 Jan;18(1):177-82. PubMed PMID: 6121772. 11: Teychenne PF, Rosin AJ, Plotkin CN, Calne DB. Cross tolerance between two dopaminergic ergot derivatives--bromocriptine and lergotrile. Br J Clin Pharmacol. 1980 Jan;9(1):47-50. PubMed PMID: 6101955; PubMed Central PMCID: PMC1429917. 12: Tadepalli AS, Novak PJ. Cardiovascular effects of bromocriptine and lergotrile in renal and spontaneously hypertensive rats. Arch Int Pharmacodyn Ther. 1983 Nov;266(1):93-105. PubMed PMID: 6141774. 13: Thorner MO, Ryan SM, Wass JA, Jones A, Bouloux P, Williams S, Besser GM. Effect of the dopamine agonist, lergotrile mesylate, on circulating anterior pituitary hormones in man. J Clin Endocrinol Metab. 1978 Aug;47(2):372-8. PubMed PMID: 45463. 14: Wade RL, Quock RM, Malone MH. Differential effects of 5-hydroxytryptaminergic antagonists upon apomorphine- and lergotrile-induced hypothermia and stereotyped behaviour in rats. J Pharm Pharmacol. 1984 Oct;36(10):673-6. PubMed PMID: 6150084. 15: Klawans HL, Goetz CG, Volkman P, Nausieda PA, Weiner WJ. Lergotrile in the treatment of parkinsonism. Neurology. 1978 Jul;28(7):699-702. PubMed PMID: 566868. 16: de Belleroche J, Gardiner IM. Action of apomorphine, bromocriptine and lergotrile on gamma-aminobutyric acid and acetylcholine release in nucleus accumbens and corpus striatum. J Neural Transm. 1983;58(3-4):153-68. PubMed PMID: 6141217. 17: Davis PJ, Glade JC, Clark AM, Smith RV. N-demethylation of lergotrile by Streptomyces platensis. Appl Environ Microbiol. 1979 Nov;38(5):891-3. PubMed PMID: 44446; PubMed Central PMCID: PMC243604. 18: Lieberman AN, Goldstein M, Leibowitz M. Comparative efficacy of two dopamine agonists, pergolide and lergotrile, in Parkinson disease. N Y State J Med. 1988 Aug;88(8):420-2. PubMed PMID: 2902541. 19: Serby M, Angrist B, Lieberman A. Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease. Am J Psychiatry. 1978 Oct;135(10):1227-9. PubMed PMID: 29497. 20: Walters JR, Lakoski JM, Baring MD, Eng N. Dopamine neurons: effect of lergotrile on unit activity and transmitter synthesis. Eur J Pharmacol. 1979 Dec 7;60(2-3):199-210. PubMed PMID: 43259.